Kontogeorgos George, Horvath Eva, Kovacs Kalman, Coire Claire, Lloyd Ricardo V, Scheithauer Bernd W, Smyth Harley S
Department of Pathology, G. Gennimatas Athens General Hospital, KOFKA Bldg., 1st Floor, 154 Messogion Avenue, 115 27, Athens, Greece.
Acta Neuropathol. 2006 Jan;111(1):46-52. doi: 10.1007/s00401-005-1111-8. Epub 2005 Nov 23.
Treatment of patients with prolactin (PRL)-producing pituitary adenomas with dopamine agonists has proved successful for most cases. Dopamine agonists inhibit PRL secretion, suppress cell proliferation, and may induce apoptosis to adenoma cells. Dopamine agonists induce striking morphologic changes in the majority of treated PRL-producing adenomas. To date, these morphologic effects have been primarily described only after long-term treatment. To the best of our knowledge, no similar studies have investigated apoptotic alterations induced after short-term therapy. The purpose of this report is to describe the morphologic changes seen in PRL-producing adenomas after short-term dopamine agonist treatment. We present two cases of PRL-producing macroadenomas, both from male patients who received treatment with dopamine agonists, the first for 5 and the second for 8 days. In contrast to long-term treatment, no striking reduction of PRL immunoreactivity was noted. Slight stromal fibrosis was noted in case 1, which contained several cells all in late phase of apoptosis. In addition to typical apoptotic cells, numerous "dark" cells representing another common form of cell death were also noted. These novel findings represent characteristic features of short-term dopamine agonist treatment, which are not seen in long-term treatment.
用多巴胺激动剂治疗催乳素(PRL)分泌型垂体腺瘤患者,在大多数情况下已被证明是成功的。多巴胺激动剂可抑制PRL分泌,抑制细胞增殖,并可能诱导腺瘤细胞凋亡。多巴胺激动剂可使大多数接受治疗的PRL分泌型腺瘤发生显著的形态学改变。迄今为止,这些形态学效应主要仅在长期治疗后才有描述。据我们所知,尚无类似研究调查短期治疗后诱导的凋亡改变。本报告的目的是描述短期多巴胺激动剂治疗后PRL分泌型腺瘤的形态学变化。我们报告两例PRL分泌型大腺瘤病例,均来自接受多巴胺激动剂治疗的男性患者,第一例治疗5天,第二例治疗8天。与长期治疗不同,未观察到PRL免疫反应性显著降低。病例1中可见轻度间质纤维化,其中包含几个均处于凋亡晚期的细胞。除了典型的凋亡细胞外,还观察到许多代表另一种常见细胞死亡形式的“暗”细胞。这些新发现代表了短期多巴胺激动剂治疗的特征,而在长期治疗中未见这些特征。